Cargando…

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy

BACKGROUND: Sarcopenia is a geriatric syndrome that is characterized by the gradual muscle loss and frailty in the elderly. Meanwhile, the prevalence of prostate cancer is on the rise worldwide. Mainstay treatments for metastatic prostate cancer are androgen-deprivation therapy and taxane-based chem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohtaka, Ayako, Aoki, Hiroaki, Nagata, Masayoshi, Kanayama, Mayuko, Shimizu, Fumitaka, Ide, Hisamitsu, Tsujimura, Akira, Horie, Shigeo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Pacific Prostate Society 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424678/ https://www.ncbi.nlm.nih.gov/pubmed/30937292 http://dx.doi.org/10.1016/j.prnil.2018.04.002

Ejemplares similares

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2020)

The Impact of Increased Bladder Blood Flow on Storage Symptoms after Holmium Laser Enucleation of the Prostate
por: Saito, Keisuke, et al.
Publicado: (2015)

A preliminary oncologic outcome and postoperative complications in patients undergoing robot-assisted radical cystectomy: Initial experience
por: Muto, Satoru, et al.
Publicado: (2017)

The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma
por: Nagaya, Naoya, et al.
Publicado: (2018)

Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report
por: Nagaya, Naoya, et al.
Publicado: (2020)

Significant association between urethral length measured by magnetic resonance imaging and urinary continence recovery after robot-assisted radical prostatectomy
por: Kitamura, Kosuke, et al.
Publicado: (2019)

Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia
por: Ieda, Takeshi, et al.
Publicado: (2016)

Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2021)

Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases
por: Hirano, Hisashi, et al.
Publicado: (2023)

Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer
por: Ashizawa, Takeshi, et al.
Publicado: (2022)

Generation of transgenic mouse line with prostate-specific expression of codon-improved Cre recombinase
por: Kanayama, Mayuko, et al.
Publicado: (2018)

Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer
por: Hirano, Hisashi, et al.
Publicado: (2020)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Successful wound closure using fibrin glue for intractable neobladder‐urethral anastomosis leakage after radical cystectomy and neobladder reconstruction
por: Ishikawa, Keisuke, et al.
Publicado: (2023)

Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Une, Minami, et al.
Publicado: (2021)

Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer
por: Ide, Hisamitsu, et al.
Publicado: (2018)

Clinical use of expanded prostate cancer index composite-based health-related quality of life outcomes after robot-assisted radical prostatectomy for localized prostate cancer
por: Fukuda, Kazuhiro, et al.
Publicado: (2022)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer
por: Muto, Satoru, et al.
Publicado: (2021)

Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes
por: Nagata, Masayoshi, et al.
Publicado: (2016)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Relation between histological prostatitis and lower urinary tract symptoms and erectile function
por: Mizuno, Taiki, et al.
Publicado: (2017)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
por: Tanaudommongkon, Irin, et al.
Publicado: (2020)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Robot-Assisted Radical Cystectomy with Modified Vesica Ileale Padovana (VIP) Neobladder Configuration Using a Hybrid Approach: Initial Experience
por: Shimizu, Fumitaka, et al.
Publicado: (2023)

Erectile Dysfunction is Predictive Symptom for Poor Semen in Newlywed Men in Japan
por: Tsujimura, Akira, et al.
Publicado: (2019)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study
por: Ide, Hisamitsu, et al.
Publicado: (2014)

Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer
por: Min, Byung-Dal, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_al2npo0q4brub8isrqh6h60gbl